User profiles for Angelo Antonini
Angelo AntoniniUniversity of Padua Verified email at unipd.it Cited by 41952 |
The PRIAMO study: a multicenter assessment of nonmotor symptoms and their impact on quality of life in Parkinson's disease
We performed a multicenter survey using a semistructured interview in 1,072 consecutive
patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to …
patients with Parkinson's disease (PD) enrolled during 12 months in 55 Italian centers to …
[HTML][HTML] Valvular heart disease and the use of dopamine agonists for Parkinson's disease
R Zanettini, A Antonini, G Gatto, R Gentile… - … England Journal of …, 2007 - Mass Medical Soc
Background Ergot-derived dopamine receptor agonists, often used in the treatment of
Parkinson's disease, have been associated with an increased risk of valvular heart disease. …
Parkinson's disease, have been associated with an increased risk of valvular heart disease. …
Parkinson's disease: the non-motor issues
KR Chaudhuri, P Odin, A Antonini… - Parkinsonism & related …, 2011 - Elsevier
Non-motor symptoms (NMS) of Parkinson's disease remain the most under-appreciated and
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …
under-researched when taken as a whole. Data is emerging that it is the “totaL” burden of …
Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double …
…, K Chatamra, J Benesh, RA Lenz, A Antonini - The Lancet …, 2014 - thelancet.com
Background Levodopa is the most effective therapy for Parkinson's disease, but chronic
treatment is associated with the development of potentially disabling motor complications. …
treatment is associated with the development of potentially disabling motor complications. …
EFNS/MDS‐ES recommendations for the diagnosis of P arkinson's disease
A Berardelli, GK Wenning, A Antonini… - European journal of …, 2013 - Wiley Online Library
Background A Task Force was convened by the EFNS / MDS ‐ ES Scientist Panel on P
arkinson's disease ( PD ) and other movement disorders to systemically review relevant …
arkinson's disease ( PD ) and other movement disorders to systemically review relevant …
Clinical diagnosis of progressive supranuclear palsy: the movement disorder society criteria
…, JC Van Swieten, C Troakes, A Antonini… - Movement …, 2017 - Wiley Online Library
Background: PSP is a neuropathologically defined disease entity. Clinical diagnostic criteria,
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …
published in 1996 by the National Institute of Neurological Disorders and Stroke/Society for …
[HTML][HTML] Patterns of regional brain activation associated with different forms of motor learning
…, J Moeller, M Mentis, T Nakamura, A Antonini… - Brain research, 2000 - Elsevier
To examine the variations in regional cerebral blood flow during execution and learning of
reaching movements, we employed a family of kinematically and dynamically controlled …
reaching movements, we employed a family of kinematically and dynamically controlled …
Early-onset parkinsonism associated with PINK1 mutations: Frequency, genotypes, and phenotypes
…, MW Horstink, JA Maat-Kievit, C Sampaio, A Antonini… - Neurology, 2005 - AAN Enterprises
Objective: To assess the prevalence, nature, and associated phenotypes of PINK1 gene
mutations in a large series of patients with early-onset (<50 years) parkinsonism. Methods: The …
mutations in a large series of patients with early-onset (<50 years) parkinsonism. Methods: The …
Levodopa in the treatment of Parkinson's disease: an old drug still going strong
W Poewe, A Antonini, JCM Zijlmans… - … interventions in aging, 2010 - Taylor & Francis
After more than 40 years of clinical use, levodopa (LD) remains the gold standard of
symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other …
symptomatic efficacy in the drug treatment of Parkinson’s disease (PD). Compared with other …
[HTML][HTML] Outcome of Parkinson's disease patients affected by COVID‐19
There is extensive debate on the neurological consequences of corona virus disease 2019 (COVID-19)
and the impact this might have for patients with neurodegenerative conditions, …
and the impact this might have for patients with neurodegenerative conditions, …